Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety.
Andra M
AM
Popescu
William S
WS
Weintraub
D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000191:economics / Q000628:therapy*; D000553:Ambulatory Care / Q000191:economics; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017048:Health Care Costs; D017721:Hospital Costs; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000191:economics; D007902:Length of Stay; D010351:Patient Discharge / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000191:economics; D017534:Radial Artery; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab